Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants

2020139 citationsJournal Articlehybrid Open Access

Authors

Alan John Camm · St George's, University of London

Frank Cools · AZ Klina

Saverio Virdone · Thrombosis Research Institute

Jean‐Pierre Bassand · Thrombosis Research Institute

David Fitzmaurice · University of Warwick

Keith Alexander Arthur Fox · University of Edinburgh

Samuel Z. Goldhaber

Abstract

In GARFIELD-AF, most patients received the recommended DOAC doses according to country-specific guidelines. Prescription of nonrecommended doses was associated with an increased risk of death, mostly cardiovascular death, compared with patients on recommended doses, after adjusting for baseline factors. (Global Anticoagulant Registry in the Field-AF [GARFIELD-AF]; NCT01090362).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Cardiac Arrhythmias and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the American College of Cardiology

Volume 76, Issue 12, pp. 1425-1436

DOI: 10.1016/j.jacc.2020.07.045

Field-Weighted Citation Impact: 13.94